Saying Goodbye To The XOMA Royalty PFDs
Ligand Pharmaceuticals is set to acquire XOMA Royalty Corporation for $739 million. The deal will enhance Ligand's earnings per share and provide preferred yield benefits. XOMA shareholders will receive $39.00 per share in cash as part of the acquisition.
- ▪Ligand Pharmaceuticals will acquire XOMA Royalty Corporation for $39.00 per share in cash.
- ▪The total value of the acquisition is approximately $739 million.
- ▪This acquisition is expected to boost Ligand's earnings per share.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Dividends Analysis","item":"https://seekingalpha.com/dividends"},{"@type":"ListItem","position":3,"name":"Dividend Strategy","item":"https://seekingalpha.com/dividends/dividend-strategy"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908014-saying-goodbye-to-the-xoma-royalty-pfds"},"author":{"@type":"Person","name":"Retired…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
